Drugs

Previous studies have suggested that the drugs known as GLP-1s, or glucagon-like peptide-1 receptor agonists, could reduce addictions by targeting the brain’s reward pathways. But those studies have been small and often limited to one substance.

New guidelines, a meta-analysis and a clinical review shed light on the surgery versus nonoperative management debate.